Table 2. NIKEI test performance in estimation group (EG) and validation group (VG).

	≤0.0535		0.0536–0.2293		≥0.2294		All patients
	EG	VG	EG	VG	EG	VG	EG	VG
All patients n	128	75	19	8	15	9	162	92
F0–F2 n	128	74	16	6	6	3	150	83
F3–F4 n	0	1	3	2	9	6	12	9
Sensitivity %	100	88.9			75.0	66.7
Specifity %	85.3	89.2			96.0	96.4
PPV %	35.3	47.1			60.0	66.7
NPV %	100	98.7			98.0	96.4
Likelihood Ratio (+)	6.8	8.2			18.8	18.5
Likelihood-Ratio (−)	0.0	0.1			0.3	0.3
AUC (95% CI) EG: 0.968±0.016 (0.937; 0.998) VG: 0.961±0.023 (0.916; 1.000)

Cut-off levels and the classification of patients on the basis of the individual scores within the estimation (EG) and validation group (VG). A patient with a value below the lower cut-off level was classified as healthy (no advanced fibrosis), with a value above the upper cut-off level as morbid (advanced fibrosis). Patients with values between the cut-off levels are intermediate/not classifiable.